Chapeltown, United Kingdom
Chapeltown, United Kingdom

Time filter

Source Type

News Article | November 28, 2016
Site: www.newsmaker.com.au

In terms of revenue, the global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn and this is expected to increase to US$ 186.4 Mn by the end of 2024. Autologous Matrix-Induced Chondrogenesis (AMIC) is a biological treatment method to repair articular cartilage damage. AMIC therapy is a step wise process. Micro fracture surgery is followed by application of a bi-layer collagen I/III membrane. It slows down cartilage degeneration with an intent to avoid or delay partial or total joint replacement (e.g. knee replacement) surgery. The indications for AMIC includes Grade III or IV chondral lesions with lesion size of about 2 cm­­2 to 8cm­­2. Growth of the global Autologous Matrix-Induced Chondrogenesis market is mainly driven by increasing demand for minimally invasive procedures, rising prevalence of bone and joint disorders and a surge in sports injuries. Another prominent growth driver is the faster uptake and access along with affordable pricing. However, lack of clinical data and lack of efficient reimbursement is expected to restrain growth of the market over the forecast period. The market is segmented based on material type and regions. Based on material type, the market is segmented into Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), polylactic-co-glycolic acid (PGLA) and others. The PEG segment is expected to grow with a healthy CAGR over the forecast period, owing to its ability to be gelled into complex defects in situ using UV-light. The segment is expected to register a significant CAGR of 11.1 % during the forecast period. The Others segment, which includes PLLA, agarose-alginate, chitosan, poly (ester-ether) polydioxanone, etc. is anticipated to grow with a CAGR of 8.1%. Segments such as hyaluronic acid and collagen are expected to register a CAGR of 8.9% and 8.2% respectively over the forecast period. The PGLA segment is expected to witness a CAGR of 9.2% over the forecast period. This report assesses trends that drive growth of each segment on the global as well as regional levels and offers potential takeaways that could prove substantially useful to surgical products manufacturing companies that wish to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market. North America is anticipated to dominate the global Autologous Matrix-Induced Chondrogenesis (AMIC) market with maximum market share in 2016. North America is expected to account for more than 38% of the total Autologous Matrix-Induced Chondrogenesis (AMIC) market share in terms of value in 2016. Followed by North America, Europe is one of the established markets for AMIC. Europe contributes to around 34% of the total market share in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 10.3% over the forecast period, due to higher adoption of AMIC procedures in the region. Some key players in the global Autologous Matrix-Induced Chondrogenesis (AMIC) market identified in the report include Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc, and Zimmer Biomet Holdings. Persistence Market Research has discussed individual strategies of these companies in terms of increasing focus on overcoming major hindrances through innovation and enhancing the distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market.


The global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn. Growth of the global Autologous Matrix-Induced Chondrogenesis market is mainly driven by increasing demand for minimally invasive procedures, rising prevalence of bone and joint disorders and a surge in sports injuries. Another prominent growth driver is the faster uptake and access along with affordable pricing. However, lack of clinical data and lack of efficient reimbursement is expected to restrain growth of the market over the forecast period. The market is segmented based on material type and regions. Based on material type, the market is segmented into Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), polylactic-co-glycolic acid (PGLA) and others. The PEG segment is expected to grow with a healthy CAGR over the forecast period, owing to its ability to be gelled into complex defects in situ using UV-light. The segment is expected to register a significant CAGR of 11.1 % during the forecast period. The others segment, which includes PLLA, agarose-alginate, chitosan, poly (ester-ether) polydioxanone, etc. is anticipated to grow with a CAGR of 8.1%. Segments such as hyaluronic acid and collagen are expected to register a CAGR of 8.9% and 8.2% respectively over the forecast period. The PGLA segment is expected to witness a CAGR of 9.2% over the forecast period. North America is anticipated to dominate the global Autologous Matrix-Induced Chondrogenesis (AMIC) market with maximum market share in 2016. North America is expected to account for more than 38% of the total Autologous Matrix-Induced Chondrogenesis (AMIC) market share in terms of value in 2016. Followed by North America, Europe is one of the established markets for AMIC. Europe contributes to around 34% of the total market share in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 10.3% over the forecast period, due to higher adoption of AMIC procedures in the region. View and Download Report Table of Contents, Figures, and Tables@ http://www.persistencemarketresearch.com/market-research/autologous-matrixinduced-chondrogenesis-market/toc "Persistence Market Research has discussed individual strategies of these companies in terms of increasing focus on overcoming major hindrances through innovation and enhancing the distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market". Some key players in the global Autologous Matrix-Induced Chondrogenesis (AMIC) market identified in the report include Anika Therapeutics, Inc., Arthro-Kinetics, B. Braun Melsungen AG, BioTissue AG, CartiHeal, Geistlich Pharma AG, JRI Orthopaedics Ltd., Matricel GmbH, Smith & Nephew plc, and Zimmer Biomet Holdings. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Trademark
JRI Orthopaedics Ltd | Date: 2016-03-01

Chemical compositions for use in the production of surgical implants, orthopaedic implants, prostheses and their components; resorbable chemical compositions for use in the production of surgical implants, orthopaedic implants and prostheses; chemical compositions for use as bone substitutes; synthetic material used to manufacture surgical implants and prostheses coatings and used to coat surgical implants and prostheses during manufacture. Surgical implants comprised of artificial materials; prostheses, namely, bone, shoulder, knee, hip, joint, leg, foot, arm and hand prostheses.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 96.54K | Year: 2016

After years of work funded by Innovate UK, a UK partnership of two SMEs, JRI Orthopaedics and GTS are looking to scale up a new functional coating for orthopaedic implants. This will combine two successful technologies: 1) bioactive glasses and 2) 3D printed implants with complex shapes. This project will enable JRI to expand the range of its joint replacements to include highly-complex implants that are tailored to an individual. This is often required if an existing implant has begun to fail and needs to removed, or if the anatomy is unusual, such as after an accident or any growth abnormalities from birth. This project will allow the partners to check that what works in the lab can be made in large enough quantitities for it to be sold around the world. Then JRI, who already sell its own implants around the world, will ensure it gets the necesssary approval to be able to launch across the globe. This partnership will be able to make and sell these implants completely - starting with raw materials all the way through to the final sales: hopefully another Made in Britain success story.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 490.03K | Year: 2013

This project brings together a consortium of complementary academic and commercial organisations, including: specialists in ultra-fast lasers, materials and orthopaedic implants. The aim is to develop new technology to allow surgeons to customise joint replacements at the time of surgery on the rare occasions when there is significant bone loss either from a failed implant that needs to be revised or from bone cancer. The technology will involve hand held lasers and new orthopaedic biomaterials tuned to be laser melted without raising the temperature of the surrounding bone. The technology developed during this project has the potential to transform treatment of these complex cases and has application in other fields requiring rapid maufacturing without raising temperatures.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 425.39K | Year: 2013

This project brings together partners with expertise in additive manufacturing, glass technology and orthopaedic implants. The aim is to develop the next generation of coatings for orthopaedic implants such as hip replacements. The new combination glass and metal coatings will have better mechanical stability and faster integration with bone thus improving long-term clinical performance and reducing the revision rate. This will deliver a significantly better clinical outcome for patients and savings for the health service. The technology developed during this project has the potential to transform the manufacture of orthopaedic implants and has applications in other fields requiring specialist combinations of glass and metal.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 388.60K | Year: 2013

Early stage osteoarthritis (OA) of the knee and shoulder can be treated using Minimally Invasive Surgery (MIS), with such techniques having become widely adopted. In contrast, treatment of the OA in the hip is far more difficult as the joint is deep in the body and spherical. Variance between patients and the stiffness of the hip joint capsule and muscles makes access into and around the hip space very difficult because current arthroscopes are too large and operate with a line-of-sight. Consequently, hip arthroscopy remains limited with low adoption. Our project seeks to overcome current limitations and develop a platform for ultra MIS equipment that is both small and curvilinear, to enable complete access to hip lesions that are currently out-of-reach. We seek to develop two prototype MIS tools. One that can accurately prepare the lesions to remove diseased cartilage and reveal the healthy bone below, and another to deliver new generative medicinal products into the target site.


Grant
Agency: Cordis | Branch: H2020 | Program: SME-1 | Phase: SMEInst-05-2016-2017 | Award Amount: 71.43K | Year: 2016

Osteoarthritis (OA) affects about 10% of the global population. It has a major impact on a patients quality of life; with pain and physical function being worse than chronic obstructive pulmonary disease or even cardiovascular disease. Its prevalence is increasing, by 2020 it will be the 4th leading cause of disability. OA is caused by wear and tear and currently only symptoms are treated using pain killers until major surgery is needed, then the joint is replaced. Although joint replacements have improved and often last over 30 years, they do fail with about 10% of all joint replacement operations being to fix a failed implant. In this project JRI is working with University Medical Center Utrecht (UMCU), The Netherlands and the Cell and Gene Therapy Catapult (CGT), UK, to develop a new treatment of OA in the hip and take it to market. This involves catching the disease early when it appears as a distinct lesion. JRI has developed Hummingbird, a system that can get into the complex anatomy of the hip and precisely cut out patches of diseased tissue. Then treating these patches with a cell-based treatment developed by UMCU and successfully used to treat OA in the knee. JRI believes that this treatment can be provided at a competitive price and at a scale to meet the global market. However, to do this they will need to build a robust business case and define in detail the regulatory pathways to the markets in Europe and USA. They will do this by working with CGT. This Feasibility Study is the first phase of this work. With CGT, JRI will define: the regulatory pathway, the cost of providing the treatment, the reimbursement methods and the likely market share. The second phase will be in the first-in-human study and a critical step in both meeting the regulations and defining the benefits to this cell-based treatment being applied to the hip. This treatment may not cure OA, but should delay major joint surgery and, in time, may allow some to avoid it all together.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 621.22K | Year: 2014

Additive Manufacturing (AM) has the potential to revolutionise the design, production and supply of parts, but exploitation has been limited. A major challenge for industry is to understand the true capability of the new techniques - especially making comparisons between machine platforms. The ANVIL project will overcome this issue, by bringing together key end-user sectors and AM experts to develop a standard way of assessing the capability of metal powder bed fusion processes. This approach will be used to compare the latest machines and the information generated will form the basis of an interactive design for AM guide. Application demonstrators will be designed using this guide and manufactured to provide case studies for promoting the effective use of AM technology. An AM-OLR (On-Line Resource) will be established to disseminate the findings and encourage sharing of data across the UK AM sector.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 545.36K | Year: 2017

Osteoarthritis (OA) the disease that this project targets, imposes massive burden on society not only in terms of loss of quality of life for the individual, but also in terms of costs – directly to the Health Services for their treatment and indirectly from loss of earnings and impact on their carers: and it is getting worse. Despite this, treatment is often only for symptoms such as pain until the disease has progressed far enough to warrant joint replacement surgery. There are some exciting new approaches to the early stages of this disease, in which the joint surface is regenerated and not replaced. However, today these require a surgical procedure in which the joint is fully opened. In this project the three partners (two SMEs: JRI and Spheritech, and University of Cambridge) will for the first time ever develop a biomaterial that can be implanted using ‘keyhole’ (arthroscopy) or open surgery, specifically to regrow the joint surface in the early-stages OA. The biomaterial, Proliferate® has been used successfully to regenerate many tissues already including, skin, liver and nerves. This project will give all the evidence needed to take it into the clinic, get a CE mark and start treating patients with OA early before total joint replacement is their only option.

Loading JRI Orthopaedics Ltd. collaborators
Loading JRI Orthopaedics Ltd. collaborators